Update: On September 1, 2020, BRDD revised its Report to correct the “Biosimilars: Market Authorizations” tables.
The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD; formerly BGTD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for Fiscal Year 2019-2020. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical, and non-prescription and disinfectant drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2015-2016 to 2019-2020.
Related Publications & Articles
-
2020 Highlights in Canadian Life Sciences IP and Regulatory Law
In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
First year of Project Orbis leads to 38 approvals of cancer therapies, including 8 by Health Canada
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence recently published an overview of Project Orbis and the regulatory actions within the first year of its implementation (June 2...Read More -
Brexit prompts amendment to CSP Regulations
On December 21, 2020, the CSP Regulations were amended to add the U.K. as a “prescribed country” for the purpose of determining the timeliness of the CSP applicant’s New Drug Submission.Read More